NVS Phase 3 cardiovascular trial misses primary endpoint
NVS says its Phase 3 cardiovascular disease trial did not meet the primary endpoint.
Story updates
08:37:43 PM UTC
SquawkNews
Ad hoc announcement pursuant to Art. 53 LRBasel, September 4, 2026 — Novartis today announced that the pelacarsen phase III Lp(a)HORIZON trial, a pioneering cardiovascular outcomes study, did not meet its primary endpoint of reducing the risk of cardiovascular events, a composite of cardiovascular…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.